Clinical Trial Update: The Prevention Of Postmenopausal Osteoporosis With Lasofoxifene And Cytokine Evaluation [Phase 2]

View source ↗

Summary

Completed Phase 2 trial evaluating lasofoxifene for prevention of postmenopausal osteoporosis, including cytokine assessments.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postmenopausal Osteoporosis

Drugs mentioned

• Lasofoxifene (Lasofoxifene)

Snippet

Sponsor: Ligand Pharmaceuticals | Conditions: Bone Loss | Phase 2 | Status: COMPLETED